ENDRA Life Sciences gets Nasdaq extension to Nov 20, 2024 to regain $1 bid price; 91% of Series B warrants exercised

ENDRA Life Sciences Inc.

Nasdaq Hearings Panel granted extension until November 20, 2024 to regain compliance with $1.00 minimum bid price for 10 consecutive trading days.
Company is evaluating options to evidence compliance; no immediate effect on listing or trading of NDRA common stock.
91% of Series B warrants from June 2024 public offering exercised, resulting in issuance of 15,831,864 shares of common stock.
Total outstanding common shares increased to 17,280,655 as of August 28, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.